Siena et al. [114] studied the mechanism of secondary resistance in EGFR inhibitor-treated patients finding new KRAS mutations in 7.1% and 57.1% of patients whose tumor genotype was determined using tissue­based and plasma­based analyses, respectively, during treatment with the combination of irinotecan and panitumumab. This evidence concerns the gene KRAS and neoplasm.